TY - JOUR
T1 - Different Factors Associated with 2-Year Outcomes in Patients with Branch versus Central Retinal Vein Occlusion Treated with Ranibizumab
AU - Sophie, Raafay
AU - Wang, Pin wen
AU - Channa, Roomasa
AU - Quezada-Ruiz, Carlos
AU - Clark, Ann
AU - Campochiaro, Peter A.
N1 - Funding Information:
Funded by Genentech, Inc., South San Francisco, California. Genentech, Inc., participated in the design and conduct of the studies; data collection, analysis, and interpretation of results; and review and approval of the manuscript. Financial Disclosure(s): The author(s) have made the following disclosure(s): P.A.C.: Consultant – Aerpio, Alimera, Allegro, Allergan, Applied Genetic Technologies, AsclepiX, Genentech, Inc./Roche, Graybug, Intrexon, Merck, Regenxbio, RXi; Personal financial interest – Allegro, Graybug; Financial support – Aerpio, Alimera, Allegro, Allergan, AsclepiX, Genentech, Inc./Roche, Genzyme, Oxford Biomedica, Regeneron, Regenxbio, RXi; and the George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience. Obtained funding: Wang, Channa, Ruiz, Clark, Campochiaro
Publisher Copyright:
© 2019 American Academy of Ophthalmology
PY - 2019/12
Y1 - 2019/12
N2 - Purpose: To investigate characteristics associated with visual and anatomic outcomes in branch and central retinal vein occlusion (BRVO and CRVO) patients treated with ranibizumab. Design: Post hoc analysis of patients with BRVO and CRVO from 2 multicenter clinical trials who completed month 12 of the HORIZON extension trial. Participants: 205 patients with BRVO and 181 patients with CRVO who completed month 12 of the extension trial. Methods: With the use of logistic regression, covariates with a P value < 0.20 from univariate analysis were included in multivariate models to identify independent factors associated with a given outcome (at P < 0.05), with preset variables of disease duration and original treatment assignment. Main Outcome Measures: Best-corrected visual acuity (BCVA) ≥20/40 (≥70 letters), gain ≥15 letters, and central subfield thickness (CST) ≤250 μm at HORIZON month 12. Results: In patients with BRVO, good baseline BCVA (odds ratio [OR], 1.53; 95% confidence interval [CI], 1.30–1.79), male sex (OR, 2.48; 95% CI, 1.20–5.13), and normal hematocrit (low vs. normal, OR, 0.26; 95% CI, 0.12–0.59) predicted BCVA ≥20/40; high central foveal thickness (OR, 1.03; 95% CI, 1.01–1.04) and normal hematocrit (low vs. normal, OR, 0.31; 95% CI, 0.15–0.66) predicted BCVA improvement ≥15 letters; and extensive baseline subretinal fluid modestly predicted CST ≤250 μm (OR, 1.08; 95% CI, 1.00–1.16). In patients with CRVO, good baseline BCVA (OR, 1.59; 95% CI, 1.35–1.89), never smoking (OR, 2.80; 95% CI, 1.27–6.17), and young age (OR, 0.58; 95% CI, 0.41–0.82) predicted BCVA ≥20/40; never smoking (OR, 2.13; 95% CI, 1.03–4.39), young age (OR, 0.41; 95% CI, 0.28–0.59), poor baseline BCVA (OR, 0.82; 95% CI, 0.73–0.93), hypertension (OR, 4.47; 95% CI, 1.70–11.75), and low diastolic ocular perfusion pressure (OPP) throughout the study (OR, 0.39; 95% CI, 0.21–0.72) predicted BCVA improvement ≥15 letters; and young age (OR, 0.65; 95% CI, 0.47–0.90), lower mean hematocrit (low vs. normal, OR, 2.81; 95% CI, 1.06–7.49), high systolic OPP throughout the study (OR, 1.61; 95% CI, 1.14–2.27), large areas of central hemorrhage (OR, 1.44; 95% CI, 1.04–2.00), and no subretinal fluid (OR, 2.15; 95% CI, 1.06–4.40) predicted CST ≤250 μm. Conclusions: There are substantial differences in good outcome factors in CRVO versus BRVO, suggesting differences in pathophysiology. Young age, never smoking, hemodilution, and hypertension/high systolic perfusion pressure are more beneficial in CRVO, suggesting that avoidance of sluggish blood flow and maintenance of perfusion may be particularly important in CRVO.
AB - Purpose: To investigate characteristics associated with visual and anatomic outcomes in branch and central retinal vein occlusion (BRVO and CRVO) patients treated with ranibizumab. Design: Post hoc analysis of patients with BRVO and CRVO from 2 multicenter clinical trials who completed month 12 of the HORIZON extension trial. Participants: 205 patients with BRVO and 181 patients with CRVO who completed month 12 of the extension trial. Methods: With the use of logistic regression, covariates with a P value < 0.20 from univariate analysis were included in multivariate models to identify independent factors associated with a given outcome (at P < 0.05), with preset variables of disease duration and original treatment assignment. Main Outcome Measures: Best-corrected visual acuity (BCVA) ≥20/40 (≥70 letters), gain ≥15 letters, and central subfield thickness (CST) ≤250 μm at HORIZON month 12. Results: In patients with BRVO, good baseline BCVA (odds ratio [OR], 1.53; 95% confidence interval [CI], 1.30–1.79), male sex (OR, 2.48; 95% CI, 1.20–5.13), and normal hematocrit (low vs. normal, OR, 0.26; 95% CI, 0.12–0.59) predicted BCVA ≥20/40; high central foveal thickness (OR, 1.03; 95% CI, 1.01–1.04) and normal hematocrit (low vs. normal, OR, 0.31; 95% CI, 0.15–0.66) predicted BCVA improvement ≥15 letters; and extensive baseline subretinal fluid modestly predicted CST ≤250 μm (OR, 1.08; 95% CI, 1.00–1.16). In patients with CRVO, good baseline BCVA (OR, 1.59; 95% CI, 1.35–1.89), never smoking (OR, 2.80; 95% CI, 1.27–6.17), and young age (OR, 0.58; 95% CI, 0.41–0.82) predicted BCVA ≥20/40; never smoking (OR, 2.13; 95% CI, 1.03–4.39), young age (OR, 0.41; 95% CI, 0.28–0.59), poor baseline BCVA (OR, 0.82; 95% CI, 0.73–0.93), hypertension (OR, 4.47; 95% CI, 1.70–11.75), and low diastolic ocular perfusion pressure (OPP) throughout the study (OR, 0.39; 95% CI, 0.21–0.72) predicted BCVA improvement ≥15 letters; and young age (OR, 0.65; 95% CI, 0.47–0.90), lower mean hematocrit (low vs. normal, OR, 2.81; 95% CI, 1.06–7.49), high systolic OPP throughout the study (OR, 1.61; 95% CI, 1.14–2.27), large areas of central hemorrhage (OR, 1.44; 95% CI, 1.04–2.00), and no subretinal fluid (OR, 2.15; 95% CI, 1.06–4.40) predicted CST ≤250 μm. Conclusions: There are substantial differences in good outcome factors in CRVO versus BRVO, suggesting differences in pathophysiology. Young age, never smoking, hemodilution, and hypertension/high systolic perfusion pressure are more beneficial in CRVO, suggesting that avoidance of sluggish blood flow and maintenance of perfusion may be particularly important in CRVO.
UR - http://www.scopus.com/inward/record.url?scp=85072276922&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072276922&partnerID=8YFLogxK
U2 - 10.1016/j.ophtha.2019.07.018
DO - 10.1016/j.ophtha.2019.07.018
M3 - Article
C2 - 31543350
AN - SCOPUS:85072276922
SN - 0161-6420
VL - 126
SP - 1695
EP - 1702
JO - Ophthalmology
JF - Ophthalmology
IS - 12
ER -